Aspira Women's Health
Biodesix, Sera Prognostics, Aspira, Epigenomics Post Q1 Financial Results
All four companies posted net losses for the quarter, while Biodesix's results were hit by a sharp decline in COVID-19 testing revenue.
Aspira Q4 Revenues up 36 Percent
The company reported total revenues of $1.9 million, up from $1.4 million in Q4 2020, while sales of its OVA1plus test were up 23 percent.
Aspira Women's Health Preliminary Q4 OVA1 Sales up 23 Percent; Firm Details Pipeline Progess
The company also announced a five-year deal with healthcare group Axia Women's Health to provide in-house genetic carrier screening.